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Abstract
Background Since evidence-based dietary guidelines are lacking for IBD patients, they tend to follow “unguided” dietary 
habits; potentially leading to nutritional deficiencies and detrimental effects on disease course. Therefore, we compared 
dietary intake of IBD patients with controls.
Methods Dietary intake of macronutrients and 25 food groups of 493 patients (207 UC, 286 CD), and 1291 controls was 
obtained via a food frequency questionnaire.
Results 38.6% of patients in remission had protein intakes below the recommended 0.8 g/kg and 86.7% with active disease 
below the recommended 1.2 g/kg. Multinomial logistic regression, corrected for age, gender and BMI, showed that (com-
pared to controls) UC patients consumed more meat and spreads, but less alcohol, breads, coffee and dairy; CD patients 
consumed more non-alcoholic drinks, potatoes, savoury snacks and sugar and sweets but less alcohol, dairy, nuts, pasta 
and prepared meals. Patients with active disease consumed more meat, soup and sugar and sweets but less alcohol, coffee, 
dairy, prepared meals and rice; patients in remission consumed more potatoes and spreads but less alcohol, breads, dairy, 
nuts, pasta and prepared meals.
Conclusions Patients avoiding potentially favourable foods and gourmandizing potentially unfavourable foods are of concern. 
Special attention is needed for protein intake in the treatment of these patients.
Keywords Inflammatory bowel disease (IBD) · Dietary assessment · Food frequency questionnaire (FFQ) · Multinomial 
logistic regression analysis
Introduction
Inflammatory Bowel Diseases (IBD), comprising ulcera-
tive colitis (UC) and Crohn’s disease (CD), are tedious 
and incapacitating disorders, impairing quality of life of 
patients and raising healthcare costs for society [1, 2]. IBD 
is characterized by mucosal inflammation and ulceration 
of the gastrointestinal tract. In addition, IBD is known for 
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its erratic course and its varying disease behaviour; peri-
ods of severe sickness are alternated with remission [3, 4].
Recent advances in the study of genetics, gut micro-
biome and environmental factors show that the aetiology 
of IBD is highly complex and remains to be elucidated. 
Accumulating evidence points to a dysbiosis of the gut 
microbiota [5–7] and an aberrant immune response [8] in 
genetically predisposed individuals [9]; a process probably 
triggered and maintained by changes in environmental fac-
tors, including diet [10, 11]. The Western diet, defined by 
high intakes of fats and sugars and low intakes of fruits 
and vegetables [12–17] is proposed as an important risk 
factor. In addition, high intakes of energy, dairy and cheese 
[18] are also suggested as potential dietary risk factors. In 
contrast, fibres [19, 20], fruits [21–23], vegetables [21, 
22, 24], fish oil [21, 23, 25], and nuts [21, 23] are consid-
ered as potential beneficial factors. Despite comprehensive 
research on a variety of different dietary elements, it is 
hard to reach consensus since the majority of studies are 
bound to recall bias [26] and methodological issues [20, 
26, 27]. Therefore, current understanding of dietary effects 
are too inconsistent to be applicable in clinical practice 
[17, 28]. Subsequently, the recurrent question of patients: 
“What should I eat?” remains difficult to answer [29].
Despite the lack of dietary consensus, patients with 
IBD do not feel intuitively restrained to experiment with 
their diet in response to symptoms, while they are often 
already malnourished [30, 31]. Additionally, dietary 
needs of patients may differ from the general population. 
We know that protein requirements are different for IBD 
patients with active disease (1.2–1.5 g/kg) when com-
pared to the general population or IBD patients in remis-
sion (0.8–1.0 g/kg) [32–34]. When avoidance of certain 
food is not supported properly, it may result in nutritional 
deficiencies; the most common micronutrient deficiencies 
in IBD due to inadequate dietary intake are iron, calcium, 
magnesium, vitamin B9, vitamin D and vitamin K [35]. 
Commonly avoided products by patients include alcohol, 
fried foods, fruits and nuts [30, 31, 36]. Alcohol and fried 
foods have been previously suggested as risk factors. How-
ever, fruits and nuts were proposed as protective factors 
[21–23]. To evaluate whether these patients’ experiments 
deviate from common (allegedly “healthy”) dietary hab-
its, a well-designed comparison between the diet of IBD 
patients after diagnosis and the diet of the general popula-
tion is needed.
Here, we aimed to study the patients’ post-diagnosis 
habitual dietary intake compared to that of the general popu-
lation in the same geographical area using a Food Frequency 
Questionnaire (FFQ). This study focusses on differences in 
dietary intake of nutrients and food groups between disease 




This case control study was embedded within the Gronin-
gen 1000IBD cohort [37] and the Lifelines DEEP Cohort 
(LLD) [38]. The 1000IBD cohort is part of the “Parels-
noer” Initiative (PSI) [39], established by the Dutch Fed-
eration of University Medical Centre to optimize clinical 
bio-banking within the eight Dutch university medical 
centres for research purposes. As part of PSI protocols 
(described elsewhere [40]), IBD patients are monitored 
closely and followed-up prospectively using structured 
questionnaires and standardized approaches.
Study population
In the context of PSI, dietary data of outpatients of the 
1000IBD cohort were obtained via an FFQ [41, 42]. For 
547 patients within the 1000IBD cohort dietary data were 
available and their eligibility was screened for this study, 
Fig. 1. Participants on tube feeding (n = 3) or diagnosed 
with unclassified IBD (n = 41) have been excluded. Next, 
a quality check was performed; patients (n = 10) who had 
implausible intake regarding to estimated energy intake 
(< 800 and > 5000 kcal/day [43]) were excluded from anal-
yses. Finally, 493 (61% women; 207 UC, and 286 CD) 
were included in this study.
In the context of the LLD study, data on participant 
characteristics and habitual food intake were already 
collected, Fig. 1. For 1539 LLD participants’ data were 
available and their eligibility for this study was checked. 
Participants of the LLD study who had missing dietary 
data (n = 79) or who reported gastro-intestinal complaints 
(n = 160) have been excluded. During the quality check, 
controls (n = 3) who had implausible intake regarding to 
the estimated energy intake (< 800 and > 5000 kcal/day) 
were excluded. In the end, 1297 (56% women) healthy 
population controls were included in this study.
Dietary assessment
In both cohorts, information about post-diagnosis habitual 
dietary intake was collected between 2013 and 2016 by the 
same FFQ which was developed and validated by the nutri-
tional department of Wageningen University using stand-
ardized methods [42, 44]. This semi-quantitative FFQ, 
containing 110 food items divided into 25 food groups, 
Table S1, assessed food intakes over the previous month as 
proxy for habitual dietary intake. The NEVO table (Dutch 
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food composition table) [45] was used to calculate indi-
vidual mean consumption of food items in grams/day and 
the macronutrient content of the diet.
Clinical data
Patients’ information was extracted from medical records; 
the visit closest to the FFQ-date was used. Information was 
collected on gender, age, height, weight, Body Mass Index 
(BMI), smoking status, disease phenotype (diagnosis), dis-
ease localization, disease duration, and faecal calprotectin 
levels. Additionally, patient reported outcome measures 
(PROM) were extracted; Harvey Bradshaw Index (HBI) and 
Short Clinical Colitis Activity Index (SCCAI).
Disease activity
Björkesten et al. [46] stated that a score based on HBI and 
faecal calprotectin is a promising tool for indicating remis-
sion in patients with CD. Therefore, disease activity was 
assessed in all our patients; clinical remission [47–49] for 
CD patients and was defined as either a faecal calprotectin 
level of < 200 mg/g or an HBI < 5. This view was extrapo-
lated to UC patients; clinical remission was defined as either 
a faecal calprotectin level < 200 mg/g or a SCCAI ≤ 2.
Data analyses
Data were reported as mean ± SD or as n (%) where appro-
priate. Baseline characteristics and dietary differences 
between disease phenotype (UC vs CD) and disease activ-
ity (active vs remission) and controls were analysed using a 
t test or ANOVA and Tukey HSD or Games-Howell post hoc 
analysis. Categorical variables were tested with a χ2-test. 
False Discovery Rate (FDR) corrected for multiple testing. 
The Spearman’s Rank Correlation Coefficient was computed 
to check whether the dietary intake of our IBD population 
was too heterogenic in terms of disease duration. This was 
not the case. Additionally, we checked whether gender 
affected our analyses by stratifying for gender since dietary 
behaviour is diversiform between women and men [50] and 
gender has been noted as a major determinant in carbohy-
drate and lipid metabolism [51–53]. However, only negligi-
ble differences were found. Therefore, only overall analy-
ses are presented in this article. Nonetheless, we decided 
to correct for gender in the multinomial logistic regression 
analyses. Thus, multinomial logistic regression analysis was 
performed on food group intake, correcting for age, gender, 
and BMI. The program IBM SPSS Statistics Version 25 for 
Mac OS X was used for all analyses.
Ethical considerations
In this study, data available from the Lifelines DEEP 
cohort study and the 1000IBD cohort (falling within the 
PSI) study have been utilized. These studies are performed 
under ethical approval of the medical ethics committee of 
the UMCG (respectively, document no. METC UMCG 
LLDEEP M12.113965 and document no. METC UMCG 
1000IBD 2008.338) and according to the Helsinki Declara-
tion of 1975 as revised in 1983 [54]. All patients provided 
written informed consent to PSI/1000IBD, all controls have 
provided written informed consent to Lifelines DEEP. This 




Of all IBD patients in our study, 207 have been previously 
diagnosed with UC and 286 with CD, Table 1. There were 
more women among CD patients (67%, p = 0.001) than 
Fig. 1  Flowchart inclusion 
study population
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Table 1  Demographical and clinical characteristics of the study population
∘ Deviant number (n): smoking: UC = 164, CD = 203, active = 180, remission = 187, controls = 1281, nominal significant difference (p < 0.05): 
*between subgroup vs controls, †between CD vs UC, ‡between active vs remission; Montreal classification: A1: ≤ 16 years, A2: 17–40 year, 
A3: > 40 years. Disease activity: active disease: HBI ≥ 5/SCCAI > 2/faecal calprotectin ≥ 200, disease in remission: HBI < 5/SCCAI ≤ /faecal cal-
protectin < 200
L1 terminal ileum, L2 colon, L3 ileocolic/backwash ileitis, L4 isolated upper disease, B1 non-stricturing, non-penetrating, B2 stricturing, B3 
penetrating, P perianal disease, E1 ulcerative proctitis, E2 left-sided, E3 extensive, S0 clinical remission, S1 mild, S2 moderate, S3 severe; HBI 
Harvey Bradshaw Index; SCCAI short clinical colitis activity index
Disease phenotype Disease activity Controls
UC CD Active Remission
n = 207 n = 286 n = 241 n = 251 n = 1291
Gender (female) n (%) 109 (53) 192 (67)*† 149 (62) 151 (60) 724 (56)
Age (years) Mean (SD) 45.6 (13.7) 40.7 (14.4)*† 43.2 (15.1) 42.1 (13.7) 43.7 (13.5)
Height (cm) Mean (SD) 175 (9.9) 174 (9.8)*† 175 (10.0) 174 (9.8)* 175 (9.6)
Weight (kg) Mean (SD) 80.9 (16.3)* 75.4 (15.6)*† 77.9 (16.5) 77.5 (15.8) 77.7 (14.7)
BMI Mean (SD) 26.4 (5.3)* 25.0 (4.7)† 25.9 (5.3) 25.6 (4.8) 25.2 (4.2)
Smoking (yes)∘ n (%) 17 (10)* 63 (31)*† 43 (24) 20 (11) 242 (19)
Diagnosis
UC n (%) 207 (100) − 94 (39) 113 (45)‡ −
CD n (%) − 286 (100) 147 (61) 138 (55) −
Montreal classification
 Age
A1 n (%) 18 (9) 45 (16)† 27 (11) 36 (14)
A2 n (%) 122 (59) 190 (66) 155 (64) 157 (63)
A3 n (%) 60 (29) 45 (16) 53 (22) 52 (21)
 Localization
L1 n (%) 0 (0) 100 (37)† 45 (20) 55 (23)
L2 n (%) 192 (97) 65 (24) 118 (52) 139 (57)
L3 n (%) 6 (3) 107 (39) 65 (29) 48 (20)
L4 n (%) 1 (1) 26 (9)† 13 (5) 14 (6)
 Behaviour
B1 n (%) – 147 (51) 79 (33) 68 (27)
B2 n (%) – 98 (34) 48 (20) 50 (20)
B3 n (%) – 40 (14) 20 (8) 20 (8)
P n (%) 7 (3) 89 (31)† 39 (16) 57 (23)
 Extent (UC)
E1 n (%) 27 (13) – 11 (5) 16 (6)
E2 n (%) 64 (31) – 27 (11) 37 (15)
E3 n (%) 110 (53) – 54 (22) 56 (22)
 Severity (UC)
S0 n (%) 9 (4) – 5 (2) 4 (2)
S1 n (%) 62 (30) – 26 (11) 36 (14)
S2 n (%) 79 (38) – 41 (17) 38 (15)
S3 n (%) 54 (26) – 21 (9) 33 (13)
Disease duration (years) mean (SD) 11.9 (9.3) 12.2 (8.6) 12.2 (9.1) 12.9 (9.2) −
HBI mean (SD) − 3.49 (3.66) 4.54 (4.07) 1.54 (1.30)‡ −
SCCAI mean (SD) 1.56 (1.92) − 2.71 (2.43) 0.64 (0.77)‡ −
Faecal calprotectin (µg/g) mean (SD) 491 (1721) 323 (522) 678 (1216) 77 (48)‡ −
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among controls (56%). The age (mean ± SD) of CD patients 
(40.7 ± 14.4 years, p = 0.001) significantly differed from con-
trols (43.7 ± 13.5 years). Compared to controls, UC patients 
had a higher weight (80.9 ± 16.3 vs 77.7 ± 14.7 kg, p = 0.004) 
and BMI (26.4 ± 5.3 vs 25.2 ± 4.2, p = 0.003); whereas CD 
patients had a lower height (174 ± 9.8 vs 175 ± 9.6 cm, 
p = 0.002) and weight (75.4 ± 15.6 vs 77.7 ± 14.7  kg, 
p = 0.018). Among CD patients were more smokers (31%, 
p < 0.001), whereas among UC patients were less smokers 
(10%, p = 0.003), compared to controls (19%).
The mean SCCAI of UC patients was 1.56 ± 1.92 and 
the mean HBI of CD patients was 3.49 ± 3.66. When we 
analysed the disease phenotype subgroups reciprocally 
(UC vs CD), significant differences were observed in gen-
der (109 (53%) vs192 (67%), p = 0.001), age (45.6 ± 13.7 
vs 40.7 ± 14.4, p = 0.001) and Montreal age (A1: 18 (9%) 
vs 45 (16%), A2: 122 (59%) vs 190 (66%), A3: 60 (29%) 
vs 45 (16%), p = 0.001) height (175 ± 9.9 vs 174 ± 9.8, 
p = 0.041), weight (80.9 ± 16.3 vs 75.4 ± 15.6, p < 0.001), 
BMI (26.4 ± 5.3 vs 25.0 ± 4.7, p = 0.004), smoking status 
(17 (10%) vs 63 (31%), p < 0.001) and naturally in disease 
localization (ileal: 0 (0%) vs 100 (37%), colonic: 192 (97%) 
vs 65 (24%), ileocolonic/backwash ileitis: 6 (3%) vs 107 
(39%), p < 0.001 and isolated upper disease: 1 (1%) vs 26 
(9%), p < 0.001) and perianal disease (97 (3%) vs 89 (31%), 
p < 0.001) (Table 1).
When we compared disease activity subgroups with con-
trols, only height (174 ± 9.8 vs 175 ± 9.6 cm, p = 0.041) in 
patients in remission was significantly different.
Comparing disease activity subgroups (active vs remis-
sion), naturally patients with active disease had higher 
mean SCCAI (2.71 ± 2.43, p < 0.001), HBI (4.54 ± 4.07, 
p < 0.001) and calprotectin levels (678 ± 1216, p < 0.001) 
from patients in clinical remission; SCCAI (0.64 ± 0.77), 
HBI (1.54 ± 1.30), calprotectin (76.7 ± 48.0).
Macronutrients
Macronutrient intake of disease phenotype subgroups, 
Table 2 differed significantly in the intake of controls; UC 
patients had a lower intake of total protein (0.91 ± 0.30 vs 
0.97 ± 0.28 g/kg, p = 0.017), animal protein (0.52 ± 0.19 
vs 0.57 ± 0.20 g/kg, p = 0.005), carbohydrates (45.3 ± 6.0 
vs 46.6 ± 5.9 En%, p = 0.009) and alcohol (4.1 ± 5.9 
vs 8.2 ± 9.2 g, p < 0.001) but had a higher intake of fat 
(36.2 ± 5.5 vs 35.1 ± 5.0 En%, p = 0.026). CD patients 
also had a lower intake of total protein (0.90 ± 0.31 vs 
0.97 ± 0.28 g/kg, p = 0.001), animal protein (0.52 ± 0.21 
vs 0.57 ± 0.20 g/kg, p < 0.001) and alcohol (4.0 ± 6.9 vs 
8.2 ± 9.2 g, p < 0.001), but not of carbohydrates. However, 
CD patients additionally showed a lower intake of plant 
Table 2  Macronutrient intake of 
patients and controls
Italic represents differences that are only nominal significant and not statistical significant
Observed variables are shown as mean (SD) in grams/day, 1statistics were performed on √-transformed vari-
ables, where appropriate ANOVA or Welch and post hoc Tukey HSD tests, or Games–Howell tests are inter-
preted; BMR% = Total kilocalorie intake as percentage of Basal Metabolic Rate (Calculated with Harris Ben-
edict Equation); women: BMR = 655.0955 + (9.5634 × Weight) + (1.8496 × Length) − (4.6756 × Age); men: 
BMR = 66.4730 + (13.7516 × Weight) + (5.0033 × Length) − (6.7550*Age); En% = Macronutrient as percent-
age of total kilocalorie intake; nominal (p < 0.05) and statistical (FDR corrected; false discovery rate = 0.05) 
significant difference: *between subgroup vs controls, †between CD vs UC, ‡between active vs remission
Disease phenotype Disease activity Controls
UC CD Active Remission
n = 207 n = 286 n = 241 n = 251 n = 1291
Kilocalories 1997 (585) 1897 (639) 1925 (656) 1954 (582) 1959 (569)
BMR% 124 (35.2) 122 (41.3) 122 (39.9) 124 (38.1) 121 (33.5)
Total protein 71.9 (19.7) 66.0 (20.0)*† 67.9 (21.1)* 69.0 (19.1)* 73.8 (20.2)
g/kg 0.91 (0.30)* 0.90 (0.31)* 0.89 (0.30)* 0.92 (0.31)* 0.97 (0.28)
Plant protein 30.7 (10.5) 28.2 (10.9)*† 28.6 (11.0)* 29.9 (10.7) 30.5 (9.9)
g/kg 0.39 (0.16) 0.39 (0.16) 0.38 (0.15)* 0.40 (0.17) 0.40 (0.14)
Animal protein 41.3 (13.8) 37.8 (13.4)*† 39.3 (14.4)* 39.2 (13.0)* 43.3 (14.6)
g/kg 0.52 (0.19)* 0.52 (0.21)* 0.52 (0.21)* 0.52 (0.20)* 0.57 (0.20)
Fat 80.9 (28.4) 75.1 (30.6) 77.2 (30.8) 78.0 (28.9) 77.2 (27.3)
En% 36.2 (5.5)* 35.3 (5.7) 35.8 (5.1) 35.6 (6.1) 35.1 (5.0)
Carbohydrates 226 (75.3) 221 (82.3) 222 (81.5) 225 (77.7) 228 (70.5)
En% 45.3 (6.0)* 46.6 (6.7)† 46.1 (5.8) 45.9 (7.0) 46.6 (5.9)
Alcohol1 4.1 (5.9)* 4.0 (6.9)* 3.7 (6.6)* 4.4 (6.4)* 8.2 (9.2)
En%1 1.5 (2.3)* 1.5 (2.5)* 1.4 (2.3)* 1.7 (2.6)* 3.0 (3.2)
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protein (28.2 ± 10.9 vs 30.5 ± 9.9 g, p = 0.002) and showed 
no higher fat intake compared to controls.
UC patients differed from CD patients in the intake of 
total protein (71.9 ± 19.7 vs 66.0 ± 20.0 g, p = 0.004), plant 
protein (30.7 ± 10.5 vs 28.2 ± 10.9 g, p = 0.019), animal pro-
tein (41.3 ± 13.8 vs 37.8 ± 13.4 g, p = 0.023) and carbohy-
drates (45.3 ± 6.0 vs 46.6 ± 6.7 En%, p = 0.041).
Macronutrient intake of disease activity subgroups differed 
significantly to intake of controls; patients with active disease 
consumed less total protein (0.89 ± 0.30 g/kg vs 0.97 ± 0.28 g/
kg, p < 0.001), plant protein (0.38 ± 0.15 vs 0.40 ± 0.14 g/kg, 
p = 0.037), animal protein (0.52 ± 0.21 vs 0.57 ± 0.20 g/kg, 
p = 0.001) and alcohol (3.7 ± 6.6 vs 8.2 ± 9.2 g, p < 0.001). 
Of the patients with active disease, 86.7% had a protein 
intake < 1.2 g/kg (Fig. 2, Table 2, Table S2). Patients in 
remission had lower intakes of total protein (0.92 ± 0.31 
vs 0.97 ± 0.28 g/kg, p = 0.024), animal protein (0.52 ± 0.20 
vs 0.57 ± 0.20 g/kg, p = 0.001) and alcohol (4.4 ± 6.4 vs 
8.2 ± 9.2 g, p < 0.001). Of the patients in remission, 38.6% 
had a protein intake < 0.8 g/kg (Fig. 2, Tables 2 and 3).
No differences were seen in macronutrient intake when 
comparing disease activity subgroups; patients in remission 
vs patients with active disease.
Food groups—ANOVA
Comparing disease phenotype subgroups to controls, statisti-
cally significant differences were observed in 9 food groups 
consumed by UC patients and in 15 food groups consumed 
by CD patients, Table 3. Compared to controls, UC patients 
had lower intakes of alcohol (57.0 ± 94.5 vs 116 ± 159, 
p < 0.001), coffee (284 ± 230 vs 382 ± 275, p < 0.001), 
dairy (250 ± 171 vs 285 ± 192, p = 0.014), nuts (11.8 ± 18.0 
vs 14.3 ± 15.7, p = 0.004), pasta (22.5 ± 24.1 vs 28.1 ± 24.0, 
p < 0.001), prepared meals (46.9 ± 65.8 vs 59.4 ± 57.8, 
p < 0.001) and rice (22.5 ± 29.2 vs 27.7 ± 28.8, p < 0.001); 
and higher intakes of meat (90.9 ± 46.1 vs 82.0 ± 42.3, 
p = 0.048) and potatoes (90.4 ± 60.9 vs76.1 ± 50.8, 
p = 0.016). Compared to controls, CD patients consumed 
less alcohol (54.6 ± 105 vs 116 ± 159, p < 0.001), breads 
(126 ± 73.9 vs 135 ± 63.2, p = 0.014), cereals (4.74 ± 11.3 
vs 7.26 ± 13.3, p < 0.001), cheese (26.2 ± 27.1 vs 30.2 ± 26.8, 
p = 0.006)), coffee (304 ± 282 vs 382 ± 275, p < 0.001), dairy 
(214 ± 195 vs 285 ± 192, p < 0.001), nuts (10.2 ± 16.9 vs 
14.3 ± 15.7, p < 0.001), pasta (18.9 ± 20.5 vs 28.1 ± 24.0, 
p < 0.001), pastry (29.0 ± 30.4 vs 31.9 ± 23.3, p < 0.001), 
prepared meals (43.2 ± 47.8 vs 59.4 ± 57.8, p < 0.001), rice 
(22.1 ± 29.6 vs 27.7 ± 28.8, p < 0.001), sauces (14.8 ± 16.8 
vs 16.7 ± 14.6, p = 0.015) and vegetables (102 ± 73.1 vs 
108 ± 63.6, p = 0.049) but more non-alcoholic drinks 
(225 ± 269 vs 155 ± 196, p < 0.001) and sugar and sweets 
(38.0 ± 33.8 vs 32.4 ± 26.8, p = 0.032).
Comparing disease phenotype groups reciprocally (UC 
vs CD), UC patients consumed more dairy (250 ± 171 
vs 214 ± 195, p = 0.018) and legumes (11.7 ± 18.2 vs 
9.24 ± 22.0, p = 0.016); but less non-alcoholic drinks 
(166 ± 244 vs 225 ± 269, p = 0.003).
Disease activity subgroups were compared to controls as 
well; 10 differences were found comparing active disease 
and remission to controls. Compared to controls, patients 
with active disease consumed less alcohol (51.9 ± 102 vs 
116 ± 159, p < 0.001), cereals (5.20 ± 13.0 vs 7.26 ± 13.3, 
p = 0.002), cheese (27.2 ± 28.8 vs 30.2 ± 26.8, p = 0.030), 
coffee (303 ± 269 vs 382 ± 275, p < 0.001), dairy (229 ± 185 
vs 285 ± 192, p < 0.001), nuts (8.80 ± 11.7 vs 14.3 ± 15.7, 
p < 0.001), pasta (18.5 ± 18.0 vs 28.1 ± 24.0, p < 0.001), 
prepared meals (43.8 ± 48.4 vs 59.4 ± 57.8, p < 0.001) and 
rice (22.1 ± 30.0 vs 27.7 ± 28.8, p < 0.001) but more pota-
toes (92.6 ± 71.9 vs 76.1 ± 50.8, p = 0.016). Patients in 
remission consumed less alcohol (59.2 ± 100 vs 116 ± 159, 
Fig. 2  Total protein intake of 
patients and recommended 
protein requirements
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p < 0.001), coffee (290 ± 254 vs 382 ± 275, p < 0.001), dairy 
(227 ± 186 vs 285 ± 192, p < 0.001), nuts (12.9 ± 21.3 vs 
14.3 ± 15.7, p = 0.012), pasta (22.3 ± 25.4 vs 28.1 ± 24.0, 
p < 0.001), prepared meals (45.7 ± 62.7 vs 59.4 ± 57.8, 
p < 0.001), rice (22.6 ± 29.0 vs 27.7 ± 28.8, p < 0.001) and 
sauces (15.3 ± 16.1 vs 16.7 ± 14.6, p = 0.047) but more non-
alcoholic drinks (204 ± 263 vs 155 ± 196, p = 0.041) and 
sugar and sweets (38.4 ± 32.1 vs 32.4 ± 26.8, p = 0.011).
Comparing disease activity groups reciprocally (active 
vs remission); patients with active disease consumed less 
nuts (8.80 ± 11.7 vs 12.9 ± 21.3, p = 0.010) than those in 
remission.
Food groups—multinomial logistic regression
Results of the multinomial logistic regression analyses, cor-
recting for age, gender and BMI, are shown in Table S3. 
Compared to controls, it was more likely that UC patients 
had a higher intake of meat and spreads, but a lower intake of 
alcohol, breads, coffee and dairy; CD patient consumed more 
non-alcoholic drinks, potatoes, savoury snacks and sugar and 
sweets but less alcohol, dairy, nuts, pasta and prepared meals. 
Moreover, compared to controls, patients with active disease 
tend to eat/drink more meat, soup and sugar and sweets but 
less alcohol, coffee, dairy, prepared meals and rice; patients 
in remission took in more potatoes and spreads but less alco-
hol, breads, dairy, nuts, pasta and prepared meals.
Discussion
To summarize our finding: patients consumed less protein 
than controls; 38.6% of patients in remission had a pro-
tein intake < 0.8 g/kg and 86.7% with active disease had a 
Table 3  Univariate comparison 
of food group intake between 
patients and controls
Italic represents differences that are only nominal significant and not statistical significant
Observed variables are shown as mean (SD) in grams/day, 1statistics were performed on √-transformed 
variables; where appropriate ANOVA or Welch and post hoc Tukey HSD tests, or Games–Howell tests are 
interpreted; nominal (p < 0.05) and statistical (FDR corrected; false discovery rate = 0.05) significant differ-
ence: *between subgroup vs controls, †between CD vs UC, ‡between active vs remission
Food  groups1 Disease phenotype Disease activity Controls
UC CD Active Remission
n = 207 n = 286 n = 241 n = 251 n = 1291
Alcohol 57.0 (94.5)* 54.6 (105)* 51.9 (102)* 59.2 (100)* 116 (159)
Breads 136 (67.3) 126 (73.9)* 127 (74.5) 133 (68.3) 135 (63.2)
Cereals 6.78 (14.4) 4.74 (11.3)* 5.20 (13.0)* 5.95 (12.5) 7.26 (13.3)
Cheese 28.1 (24.0) 26.2 (27.1)* 27.2 (28.8)* 26.5 (22.2) 30.2 (26.8)
Coffee 284 (230)* 304 (282)* 303 (269)* 290 (254)* 382 (275)
Dairy 250 (171)* 214 (195)*† 229 (185)* 227 (186)* 285 (192)
Eggs 14.2 (15.2) 13.9 (13.5) 15.1 (15.6) 13.0 (12.7) 14.4 (14.5)
Fish 14.9 (15.7) 14.2 (16.1) 15.0 (17.5) 14.1 (14.3) 15.1 (16.0)
Fruits 219 (179) 229 (195) 229 (186) 220 (191) 223 (159)
Legumes 11.7 (18.2) 9.24 (22.0)† 10.6 (24.5) 9.90 (15.8) 9.41 (15.8)
Meat 90.9 (46.1)* 82.2 (42.4) 85.1 (46.4) 86.8 (41.7) 82.0 (42.3)
Non-alcoholic drinks 166 (244) 225 (269)*† 195 (258) 204 (263)* 155 (196)
Nuts 11.8 (18.0)* 10.2 (16.9)* 8.80 (11.7)* 12.9 (21.3)*‡ 14.3 (15.7)
Pasta 22.5 (24.1)* 18.9 (20.5)* 18.5 (18.0)* 22.3 (25.4)* 28.1 (24.0)
Pastry 33.3 (25.0) 29.0 (30.4)* 31.8 (32.5) 29.8 (23.7) 31.9 (23.3)
Potatoes 90.4 (60.9)* 84.9 (68.3) 92.6 (71.9)* 82.1 (58.1) 76.1 (50.8)
Prepared meals 46.9 (65.8)* 43.2 (47.8)* 43.8 (48.4)* 45.7 (62.7)* 59.4 (57.8)
Rice 22.5 (29.2)* 22.1 (29.6)* 22.1 (30.0)* 22.6 (29.0)* 27.7 (28.8)
Sauces 15.6 (17.1) 14.8 (16.8)* 14.9 (17.8) 15.3 (16.1)* 16.7 (14.6)
Savoury snacks 17.5 (15.8) 19.1 (22.3) 18.8 (21.6) 18.1 (18.0) 17.7 (16.4)
Soup 52.9 (64.2) 42.8 (49.1) 45.1 (57.8) 49.0 (54.5) 45.9 (54.8)
Spreads 24.3 (18.6) 22.2 (19.6) 23.5 (19.7) 22.7 (18.7) 21.7 (15.9)
Sugar and sweets 36.2 (28.2) 38.0 (33.8)* 36.2 (31.0) 38.4 (32.1)* 32.4 (26.8)
Tea 279 (257) 268 (267) 265 (253) 279 (273) 243 (242)
Vegetables 108 (65.5) 102 (73.1)* 104 (71.8) 105 (68.5) 108 (63.6)
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protein intake < 1.2 g/kg. Furthermore, patients consumed 
less potentially unfavourable food groups such as alcohol, 
pasta and prepared meals. But they consumed more of poten-
tially unfavourable food groups such as meat, non-alcoholic 
drinks, and sugar & sweets. Moreover, a higher intake of 
savoury snacks and spreads was reported in patients. Addi-
tionally, patients avoided potential favourable foods such as 
breads, coffee, dairy, nuts and rice. However, they consumed 
more of the potential favourable foods such as potatoes and 
soup.
The guidelines from the European Society for Clinical 
Nutrition and Metabolism (ESPEN) recommend adult IBD 
patients with active disease to increase their protein require-
ment to 1.2–1.5 g/kg body weight/day [32], whereas in the 
general population only 0.8 g/kg body weight/day is recom-
mended [33, 34]. Despite these increased recommendations, 
we observed that our IBD patients had a lower protein intake 
than controls; 86.7% of the patients with active disease did 
not meet the increased recommended protein intake of 1.2 g/
kg/day. This higher intake is recommended in these patients 
due to protein losses caused by e.g. inflammation in the gas-
trointestinal tract [33]. Too low protein intake might lead to 
muscle mass loss. Recently, it was demonstrated that appen-
dicular skeletal muscle index, an indicator of muscle mass, 
significantly decreases in patients within two year after 
being diagnosed with IBD [55]. Besides, these patients tend 
to consume less animal protein which is of higher nutritional 
value, since animal protein, in contrast to plant protein, 
contains all essential amino-acids. On the other hand, high 
protein intake could impact the gut microbiota composition 
and thereby inducing some typical feature of IBD-associated 
dysbiosis [34]. In addition to quantity, it might be that the 
source of proteins (animal not plant) may modulate the risk 
[34]. Among animal protein sources, high intakes of meat 
or fish but not of eggs or dairy products has been related to 
the risk on IBD [56]. Therefore, the source of protein should 
be taken into consideration when advising patients with IBD 
to increase their protein intake in a allegedly healthy manner 
(i.e. complementation of plant protein sources [57]).
Since evidence-based dietary guidelines are lacking for 
patients with IBD, proper research into dietary effects on 
IBD and its course is urgently needed. We studied patients’ 
habitual dietary intake in comparison to controls. In the light 
of current available evidence, we will discuss the intake of 
food groups as potentially “unfavourable” or “favourable”, 
since the intake of unguided diets may lead to potential 
unwanted effects on disease course.
We reported that patients had lower intakes of potential 
unfavourable foods like alcohol, pasta and prepared meals. 
Avoidance of alcohol is one of these sensible alterations, 
consumption of alcohol increases the risk on relapse by 2.7 
times [58]. Thus, this alteration may help patients to stay in 
remission. Furthermore, prepared meals are demonstrated 
to lead to a 2.9-fold increased risk of UC, and 2.3-fold 
of CD [59]. On the other hand, IBD patients have higher 
intakes of certain potential unfavourable foods. Our patients 
consumed more meat, non-alcoholic drinks and sugar and 
sweets. Although meat, especially red and processed meat, 
was identified as potential risk for IBD [56, 58, 60–64], 
our UC patients and those with active disease had a higher 
meat intake which can potentially lead to aggravation of 
symptoms [31, 36, 65]. The higher consumption of non-
alcoholic beverages might be compensatory to a lower intake 
of alcoholic beverages. This is of concern, as some non-
alcoholic beverages have been reported as risk factor for 
IBD; for example, cola, a popular non-alcoholic drink, was 
reported to increase the risk for UC 1.6 times and that for 
CD 2.2 times [66]. Several studies [21, 22, 67] identified 
sugar as a risk factor for IBD. Unfortunately, our CD patients 
and patients with active disease consumed more sugar and 
sweets when compared to controls. Perhaps, this might be 
explained by the invisibility of sugars. They may consume 
more sugar than they realize when they are using (alterna-
tive) products. Furthermore, there is not enough evidence 
available to classify savoury snacks and spreads as poten-
tial (un)favourable food groups [68]. Savoury snacks are 
reported to be consumed more by CD patients than controls. 
Spreads are consumed frequently by CD patients [68], and 
also by our UC patients and patients in remission.
Additionally, patients avoided potentially favourable 
foods too; patients consumed less breads, coffee and dairy 
compared to controls. Moreover, less nuts were consumed 
by CD patients and patients who are in remission. Besides, 
less rice was eaten by patients with active disease. Breads 
and cereals are major sources of fibre and are identified as 
protective to IBD [22]. Only a few studies reported patients 
having experienced complaints due to intake of bread and 
cereals [30, 65]. Nevertheless, patients avoided these food 
groups. This might be due to a hype among IBD patients of 
adapting a gluten-free diet [69]. Besides, yeast, commonly 
present in bread, is reported to be harmful for IBD patients 
[70]. Several studies report that patients avoid coffee due to 
aggravated symptoms [30, 31, 36]. Though, coffee is sug-
gested to be beneficial in IBD in a few studies [67, 71]. 
However, the exact mechanism of coffee is unclear [72]. 
In our study we found a lower coffee consumption in UC 
patients and patients with active disease. Dairy products are 
reported to be commonly avoided by patients as well [73, 
74]. Disease relapse was not associated with dairy intake 
[75] and as an animal protein source, dairy was not associ-
ated with the risk on IBD [56]. Recently, yoghurt, buttermilk 
and fermented milk have demonstrated an anti-inflammatory 
effect in vitro [76]. Avoidance of dairy leads to increased 
risk of low calcium levels and osteoporosis [77], as com-
monly seen in 20–50% of the IBD patients already [70]. Nuts 
are a natural source of sulphur which is potentially causing 
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greater risk on relapses in UC patients [19, 58]. Neverthe-
less, nuts are suggested to be protective in the development 
of CD [21, 23]. Rice is reported to improve symptoms [31], 
nonetheless, patients with active disease had a lower intake. 
Soup on the other hand, is likely consumed more by our 
patients with active disease as it is reported to be potentially 
beneficial [31]. Additionally, more potatoes are consumed 
by CD patients and patients in remission. Potatoes contain 
glycoalkaloid that aggravated intestinal inflammation in 
predisposed mice [78]. On the other hand, resistant starch 
in potatoes might be beneficial in IBD [79]. Superiority of 
pasta, rice and potatoes to each other in IBD patients can-
not be deducted from literature [61]. Pasta was not directly 
associated with an increased risk on developing UC. How-
ever, Maconi et al. [61] reported an positive association 
between adapting to a “refined” dietary pattern (including 
pasta, sweets, red and processed meat, butter and margarine) 
and the risk on developing IBD. In our study, patients often 
consumed less rice and pasta, but more potatoes.
The patients in our study population seemed to follow 
“unguided” dietary habits (meaning without guidance of a 
physician or dietician) based on personal feelings and expe-
riences considering diet and symptoms. Nevertheless, it is 
possible that these dietary habits were guided, since dietary 
guidance was not registered during the study period. More-
over, our patient population does include patients with 
different Montreal classifications, including penetrating/
stricturing disease. Although evidence is lacking, clinicians 
and patients do widely accept that a low-residue diet may 
be beneficial for IBD patients when having a severe flare or 
stricturing CD and obstructive symptoms [30, 80]. Hence, 
this may have influenced habitual dietary intake of patients 
in our study population. Moreover, patients were classified 
as active or in remission based on either HBI/SCCAI or 
faecal calprotectin levels. Hence, the active group had a 
mean HBI < 5 (generally regarded as clinical remission) 
but on the other hand a mean faecal calprotectin of > 200 g/
mg (cut-off clinical remission). The fact that patients did 
not have complaints (reflected in the HBI/SCCAI score), 
may have influenced their eating habits as well. Intakes of 
IBD patients were compared to intakes of controls. Our 
control population consists of Lifelines DEEP [38] par-
ticipants, a subgroup of the Lifelines cohort study. The 
intake of the complete cohort is described elsewhere and 
can be considered as representative for the intake in the 
Netherlands.[81]
We acknowledge the limitations appurtenant to an FFQ, 
moreover this FFQ did not obtain direct data on fat type, 
fibre, salt intake and micronutrient intake (e.g. calcium). 
Furthermore, since IBD patients tend to eat small quanti-
ties of food each time, an FFQ might underestimate their 
true dietary intake. Dietary intake was only assessed once in 
this study, ignoring seasonal differences in habitual intake, 
nevertheless FFQs are an appropriate method to assess long-
term dietary intake [82]. For future use we recently devel-
oped an IBD specific FFQ [83]. Besides, dietary guidance 
was not registered, therefore the reasoning of patients behind 
why they adapt to a certain diet is lacking. Strengths of this 
study are the inclusion of a large population-based sample 
set embedded within two prospective cohorts, and the use 
of a validated FFQ to assess dietary intake, while statis-
tical analyses controlled for potential confounding factors 
like age, gender and BMI. Furthermore, we assessed food 
intakes of UC and CD patients separately and could distin-
guish between patients with active disease or in remission.
Conclusions
In conclusion, our study confirms that there are several 
relevant differences in habitual dietary intake of patients 
compared to controls; patients avoid potentially favourable 
food groups such as breads, coffee, dairy, nuts and rice, 
and gourmandize potentially unfavourable food groups 
like meat, non-alcoholic drinks and sugar and sweets. This 
might attribute to potentially unintended effects on disease 
course and its complications. To be able to propose bet-
ter dietary guidelines for IBD patients, more research into 
dietary effects on IBD disease course is urgently needed. A 
major concern is the lower protein intake; further attention 
to protein intake is needed in future studies and in the treat-
ment of these patients, especially in those with active disease 
when protein needs are increased.
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